Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
28.71
-0.17 (-0.59%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Pfizer
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
99
100
Next >
PFE Stock Earnings: Pfizer Beats EPS, Beats Revenue for Q1 2024
May 01, 2024
PFE stock results show that Pfizer beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Pfizer Q1 Earnings and Revenues Beat Estimates
May 01, 2024
PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago.
Via
Talk Markets
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
May 01, 2024
Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and Paxlovid revenues countered by operational gains. Company announces plans for...
Via
Benzinga
Exposures
COVID-19
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
May 01, 2024
Discover GSK's first-quarter performance, boasting a 10% Y/Y sales surge to £7.4 billion. Notable growth in Vaccines and Specialty Medicines, propelled by strong demand for Arexvy and Shingrix....
Via
Benzinga
Pfizer Jumps After Raising Its Outlook On The Heels Of A Big Quarterly Beat
May 01, 2024
The company raised its earnings outlook for the year, noting it's on track to save at least $4 billion in net costs.
Via
Investor's Business Daily
(PFE) - Analyzing Pfizer's Short Interest
April 30, 2024
Via
Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Pfizer's Options: A Look at What the Big Money is Thinking
April 26, 2024
Via
Benzinga
Wall Street Set To Open Lower After AMD Earnings Disappoint As Traders Look To Fed's Powell For Relief: Why This Analyst Sees Incoming Summer Rally
May 01, 2024
A negative sentiment might linger on Wall Street on Wednesday, as evidenced by stock futures, after Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Investor Sentiment Falls, Dow Snaps Five-Month Win Streak
May 01, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Amazon, Pfizer And 3 Stocks To Watch Heading Into Wednesday
May 01, 2024
Via
Benzinga
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
April 30, 2024
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
April 30, 2024
Via
Benzinga
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings
April 30, 2024
Pfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has declined 34.61% YoY and -10.94% YTD due to COVID-19 revenue decrease. Technical analysis shows bearish...
Via
Benzinga
Exposures
COVID-19
5 Top Stocks to Buy in May
April 30, 2024
Whether you're looking for a proven player, passive income, or a breakout growth story, there are plenty of stocks worth buying this spring.
Via
The Motley Fool
Why I'm Buying This Beaten-Down, High-Yield Dividend Stock Hand Over Fist
April 30, 2024
The sun could be peeking through the dark clouds for Pfizer.
Via
The Motley Fool
Forget Nvidia: Prominent Billionaires Are Selling It and Buying These 2 Ultra-High-Yield Dividend Stocks Instead
April 30, 2024
Wall Street's brightest, most successful billionaire money managers are ditching Nvidia in favor of two time-tested income stocks with yields of 6.6%!
Via
The Motley Fool
mRNA Is Promising A Breakthrough In Fighting Cancer
April 29, 2024
When it comes to cancer, there’s innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as it...
Via
Benzinga
Exposures
COVID-19
3 Beaten-Down Stocks I Wouldn't Touch With a 10-Foot Pole
April 29, 2024
These stocks aren't bargains.
Via
The Motley Fool
3 Dividend Stocks to Buy on the Dip: April 2024
April 29, 2024
With the market presenting many vagaries, investors may take some solace in these dividend stocks to buy on the dip.
Via
InvestorPlace
Is Viking Therapeutics Incredibly Undervalued?
April 28, 2024
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
Via
The Motley Fool
3 High-Yield Dividend Stocks That Could Soar 22% to 49%, According to Wall Street
April 28, 2024
Whether or not these stocks hit analysts' price targets, they all should be attractive to investors seeking great income and solid growth.
Via
The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
April 27, 2024
You'll get dividends and more with these great stocks.
Via
The Motley Fool
7 Dividend Stocks to Buy Now for Steady Returns in Any Market
April 27, 2024
Passive investors pay attention! Invest in the best of the best with these seven dividend stocks for steady returns.
Via
InvestorPlace
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
April 26, 2024
Acuitas Therapeutics settles lawsuit with CureVac over COVID-19 vaccine patents. Legal disputes unfold among biotech giants Pfizer, BioNTech, and CureVac, as GSK joins the fray, alleging patent...
Via
Benzinga
Topics
Intellectual Property
Lawsuit
Exposures
COVID-19
Financial
Intellectual Property
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
April 26, 2024
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.
Via
Benzinga
Exposures
Product Safety
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
April 26, 2024
Put your money to work by investing in these three high-quality dividend stocks.
Via
The Motley Fool
Pfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
April 26, 2024
Pfizer won FDA approval for a new hemophilia B gene therapy, a rival to Hemgenix from CSL and Uniqure.
Via
Investor's Business Daily
Exposures
Product Safety
What's Going On With Pfizer Stock On Thursday?
April 25, 2024
GSK initiates legal proceedings against Pfizer and BioNTech over alleged COVID-19 vaccine patent infringement, intensifying high-stakes legal battles in the U.S.
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.
Via
Investor's Business Daily
< Previous
1
2
...
10
11
12
13
14
15
16
17
18
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.